Entrada Therapeutics Advances RNA-Based Pipeline with First Ocular Candidate for Usher Syndrome
核心洞察
Entrada Therapeutics selected ENTR-801 (搜索) as its first clinical candidate for ocular diseases, targeting Usher syndrome type 2A (搜索) through exon 13 skipping to restore usherin (搜索) protein production.
The company expects multiple data readouts in 2026 from its Duchenne muscular dystrophy (搜索) franchise, including ELEVATE-44-201 data in Q2 2026 and ELEVATE-45-201 data in mid-2026.
Entrada maintains a robust cash runway into Q3 2027 and plans to nominate a second clinical candidate in ocular diseases during 2026.
Entrada Therapeutics has announced significant progress across its RNA-based therapeutic portfolio, highlighted by the selection of ENTR-801 (搜索) as its first clinical candidate for ocular diseases targeting Usher syndrome type 2A (搜索). The clinical-stage biopharmaceutical company reported these developments as part of its expanding pipeline addressing neuromuscular and ocular diseases.
"In 2025, we strategically positioned Entrada to significantly advance what we believe to be best-in-class therapies for people living with Duchenne muscular dystrophy (搜索), and expanded our pipeline into ocular diseases with the selection of our first clinical candidate targeting Usher syndrome, an inherited retinal disorder with a profound unmet clinical need," said Dipal Doshi, Chief Executive Officer at Entrada Therapeutics.
Breakthrough in Ocular Disease Treatment
ENTR-801 (搜索) represents a novel oligonucleotide-based therapy designed for patients with Usher syndrome type 2A (搜索) who are amenable to exon 13 skipping. The clinical candidate aims to restore functional usherin (搜索) protein production with the goal of preserving photoreceptors to stabilize retinal architecture and preserve function. ENTR-801 was selected from a library of 200 sequences based on its robust exon skipping and usherin protein production, as well as initial safety demonstrated in multiple animal models.
Usher syndrome type 2A (搜索) is an inherited eye disease caused by changes in the USH2A gene (搜索). In affected individuals, mutations in exon 13 prevent the body from producing usherin (搜索), a protein essential for photoreceptor health. Without usherin, photoreceptors gradually degenerate, leading to progressive vision loss that often begins in early adulthood and can progress to legal blindness by mid-adulthood. Currently, no approved therapies address the underlying cause of Usher syndrome.
The patient population represents a significant unmet medical need, with approximately 15,000 people in the United States and Europe living with Usher syndrome type 2A (搜索) who may be amenable to exon 13 skipping.
Duchenne Muscular Dystrophy Program Advances
Entrada continues to advance multiple clinical programs for Duchenne muscular dystrophy (搜索) (DMD) across the U.K., EU, and U.S. The company expects to have four clinical-stage programs in its DMD franchise by 2026: ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51 (搜索).
The ELEVATE-44-201 study has completed dosing of Cohort 1 in the global Phase 1/2 multiple ascending dose portion for ENTR-601-44 in ambulatory patients with DMD amenable to exon 44 skipping. The company is on track to report data from Cohort 1 (6 mg/kg) in the second quarter of 2026, with data from Cohort 2 (up to 12 mg/kg) expected by year-end and Cohort 3 (up to 18 mg/kg) to follow. In December 2025, the U.S. Food and Drug Administration granted Rare Pediatric Disease Designation to ENTR-601-44.
For ENTR-601-45, the company initiated patient dosing in the global Phase 1/2 MAD study targeting ambulatory patients with DMD amenable to exon 45 skipping. Data from Cohort 1 (5 mg/kg) is expected in mid-2026, with subsequent cohorts at up to 10 mg/kg and 15 mg/kg to follow.
Regulatory Progress and Future Plans
Entrada received regulatory authorization from the U.K.'s Medicines and Healthcare Products Regulatory Agency and Research Ethics Committee to initiate a Phase 1/2 MAD clinical study of ENTR-601-50. The company expects to submit regulatory applications in the EU for ENTR-601-50 in the second half of 2026 and initiate the study by year-end. Global regulatory applications for ENTR-601-51 (搜索) are planned for 2026.
Partnership and Financial Position
The company's partnership with Vertex continues to progress, with VX-670 for myotonic dystrophy type 1 (搜索) ongoing in enrollment and dosing phases. Vertex is on track to complete enrollment and dosing in the first half of 2026.
Entrada maintains a strong financial position with cash runway anticipated into Q3 2027, providing sufficient resources to advance its expanding pipeline of intracellular therapeutics.
Technology Platform
Entrada's approach leverages its proprietary Endosomal Escape Vehicle (EEV) therapeutics platform, designed to enable efficient intracellular delivery of therapeutics into various organs and tissues. The company's pipeline includes RNA- and protein-based programs utilizing next-generation EEVs, novel oligonucleotide sequences, and an advanced protein engineering platform.
Doshi emphasized the company's strategic positioning: "2026 will be a data-rich year for our Duchenne franchise, with multiple readouts including data from the first cohort of ELEVATE-44-201 expected in the second quarter of 2026 and ELEVATE-45-201 in mid-2026. We also plan to advance our growing development portfolio of RNA-based programs and expect to nominate a second clinical candidate in ocular diseases later this year."